Immunotherapeutic Advances for NSCLC
Marco Massafra,1,* Maria Ilenia Passalacqua,1,* Vittorio Gebbia,2,3 Paolo Macrì,4 Chiara Lazzari,5 Vanesa Gregorc,5 Carmelo Buda,1 Giuseppe Altavilla,1 Mariacarmela Santarpia1 1Medical Oncology Unit, Department of Human Pathology “G. Barresi”, University of Messina, Messina, Italy; 2...
Main Authors: | Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-10-01
|
Series: | Biologics : Targets & Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/immunotherapeutic-advances-for-nsclc-peer-reviewed-fulltext-article-BTT |
Similar Items
-
Assays for predicting and monitoring responses to lung cancer immunotherapy
by: Cristina Teixidó, et al.
Published: (2015-06-01) -
Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01) -
Immunotherapy protocols in lung cancer
by: Nandini Menon, et al.
Published: (2018-01-01) -
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
by: Kim A. Brogden, et al.
Published: (2018-02-01) -
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
by: Alessandro Di Federico, MD, et al.
Published: (2021-09-01)